UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 19, 2015

 

MEDIFIRST SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   333-178825   27-3888260
State or other jurisdiction   Commission File Number   IRS Employer
incorporation       Identification No.

 

4400 Route 9 South, Suite 1000, Freehold, NJ   07728
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (732)-786-8044

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Section 5-Corporate Governance and Management

 

Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change of Fiscal Year

 

Effective November 19, 2015, the Company amended its Articles of Incorporation to increase its authorized capital to 1,500,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock. All other provisions of the Articles of Incorporation in effect prior to this amendment remained unchanged.

 

 2 

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this amended report to be signed on its behalf by the undersigned hereunto duly authorized.

 

MEDIFIRST SOLUTIONS, INC.
     
Dated: November  23, 2015 By: /s/ Bruce Schoengood
President and Chief Executive Officer

  

 3 

 

 

Exhibit 16.1 Letter from  David A. Aronson, CPA, P.A., pursuant to Item 304 of Regulation S-K

  

 

 

4

 

 



Exhibit 16.1

 

David A. Aronson, CPA, P.A.

1000 NE 176th Street

North Miami Beach, FL 33162

 

June 25, 2015

 

United States Securities & Exchange Commission

100 F Street, NE

Washington, D.C.20549

 

Ladies & Gentlemen:

 

We have read the disclosures on the Form 8K report of Medifirst Solutions, Inc. dated June 25, 2015 and we are in agreement with the statements contained therein, as they pertain to our engagement and subsequent dismissal.

 

Very truly yours,

 

/s/ David A. Aronson, CPA, P.A.